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The past years have seen an incredible increase in the quality and success rates of 
treatments in pediatric medicine. One of the resulting major challenges refers to the man-
agement of primary or secondary residual executive function deficits in affected children. 
These deficits lead to problems in the ability to acquire, understand, and apply abstract 
and complex knowledge and to plan, direct, and control actions. Executive functions 
deficits are important to consider because they are highly predictive of functioning in 
social and academic aspects of daily life. We argue that current clinical practice does 
not sufficiently account for the complex cognitive processes in this population. This is 
because widely applied pharmacological interventions only rarely account for the com-
plexity of the underlying neuronal mechanisms and do not fit well into possibly powerful 
“individualized medicine” approaches. Novel treatment approaches targeting deficits in 
executive functions in seriously ill children could focus on neuronal oscillations, as these 
have some specific relations to different aspects of executive function. Importantly, such 
treatment approaches can be individually tailored to the individuals’ deficits and can be 
transferred into home-treatment or e-health solutions. These approaches are easy-to-
use, can be easily integrated into daily life, and are becoming increasingly cost-effective.
Keywords: cognitive dysfunctions, executive function, therapy, cognitive training, chronic disease
iNtrODUctiON
In recent years, advances in pediatric medicine have led to significantly higher survival rates of 
children with serious acute or chronic life-limiting conditions (1–4). In particular, the option of 
an individual adjustment of treatment to the particular characteristics of a particular disease in 
a particular patient (5) has opened new avenues for treating clinicians. These treatment advances 
have, however, resulted in an increasing group of children and (young) adult patients with residua 
or sequelae of (often rare) childhood diseases. This introduces new problem areas, since increased 
survival is resulting in new morbidities that may significantly affect psychosocial outcomes (1, 6–8). 
Concerning this issue, questions relating to general intellectual abilities in these children and the 
development of various cognitive functions are moving more and more into the focus (9). To name 
just a few, problems in cognitive functioning that are frequently associated with various (neuro)
FigUre 1 | A large number of diseases can result in executive function deficits, which in turn significantly influence a variety of outcome variables. Various 
approaches can be applied to address such deficits. “+” denotes advantages of these intervention approaches, whereas “−” denotes disadvantages.
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psychiatric/developmental disorder have been reported to occur 
as direct primary effects or as secondary results of a number 
of devastating diseases. These include, but are not limited to, 
cancer (10, 11), congenital, and chronic developmental disorders 
affecting the nervous system like epilepsy (12), sickle cell disease 
(13), spina bifida (14), phenylketonuria (15), and neurofibroma-
tosis type 1 (16) as well as incidents significantly interfering with 
development like preterm birth (17) or traumatic brain injury 
(18, 19) (see Figure  1). We suggest that, just like it is the case 
for the underlying condition, such problems should be addressed 
through therapeutic strategies which strongly take the individual 
characteristics of deficits of the affected patients into account (see 
Table 1 and Figure 1).
ceNtrAL cOgNitive PrOcesses  
AND AssessMeNt OF eXecUtive  
(DYs)FUNctiONs
In children with previous and ongoing severe acute or chronic 
illnesses, deficits in cognition can arise due to a number of 
factors. On the one hand, such diseases can directly affect the 
central nervous system and lead to structural or functional 
alterations which then impair cognitive functions and behavio-
ral control. On the other hand, the structure and function of the 
central nervous system in these children can also be negatively 
affected by treatment, i.e., as side effects of pharmacological 
interventions, radio- and chemotherapy, and prolonged periods 
of hospitalization (20, 21). Depending on disease character-
istics, developmental aspects (esp. neuronal plasticity) and 
treatment modalities, such impairments can be temporary or 
permanent. A large variety of cognitive functions, including 
attention, language, memory, and executive functions can be 
affected in children who have survived a serious illness. Based 
on their overarching significance for academic, vocational, and 
social functioning (22, 23), this paper will focus on executive 
function deficits occurring as a result of severe somatic illnesses 
in childhood (24).
Although a variety of (in some aspects even contrasting) 
models exist concerning executive functions, there is a general 
consensus that executive functions describe the ability to acquire, 
understand, and apply abstract and complex knowledge and to 
plan, direct, and control actions (24, 25). Poor executive func-
tions have been associated with higher rates of violent crimes 
(26), risky financial behaviors (27), low social autonomy (28), 
and a generally lower quality of life (29). Executive functions 
can be examined using behavioral observations and question-
naire ratings [e.g., the behavior rating inventory of executive 
function or the learning, executive, and attention functioning 
scale (30)] and through specific neuropsychological tests like 
the behavioral assessment of the dysexecutive syndrome in 
children (31).
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cOgNitive trAiNiNg APPrOAcHes—
cUrreNt PrActice AND cAveAts
Once executive dysfunctions have been identified in the indi-
vidual child, specific neurocognitive training programs can be 
used to ameliorate such deficits (22) from preschool age onwards. 
Diamond and Lee (32) review important influencing factors and 
crucial general characteristics of potential interventions in child-
hood in great detail. Such programs focus on (i) the restoration 
of existing impairments using specific training exercises, (ii) the 
acquisition of specific compensatory techniques related to the 
organization and planning of behavior, and (iii) the modification 
of environmental factors (23). The few empirical studies that 
have examined the effects of cognitive interventions in children 
with severe acute or chronic disorders show mixed results (33, 
34). Despite some promising reports of improvements in trained 
domains such as attention and memory, inhibitory control as a 
central element of executive function was not improved after any 
of the examined interventions (33). In addition, and although 
such interventions often have a high ecological validity, the trans-
fer to other, even closely related (untrained) cognitive/executive 
functions is limited (34). Also, the quality of the available studies 
is rather low (33). Most importantly, the pathophysiological and 
neurobiological pathways leading to the deficits or to any positive 
treatment outcomes are only taken into account to a limited extent 
(33) (see Figure  1). Such a more neurobiological, mechanistic 
viewpoint on the underlying processes may significantly aid the 
development of interventions that are targeted and individually 
adjustable [i.e., conform with approaches of individualized medi-
cine (5)] (see Table 1).
DOPAMiNe-BAseD MecHANisMs 
UNDerLYiNg eXecUtive FUNctiONs
Concerning neurobiological mechanisms, executive functions 
are mainly modulated by the catecholaminergic and dopaminer-
gic system affecting fronto-striatal circuits (35, 36), even though 
serotonergic and glutamatergic mechanisms are also very impor-
tant. Broadly speaking, “optimal” performance in numerous 
aspects of executive functions is reached when intermediate levels 
of dopamine are available (37, 38). In the case of “optimal” inter-
mediate dopamine concentrations, there is an intricate balance 
between striatal dopamine D2-receptor related neural transmis-
sion (relevant for cognitive flexibility) and prefrontal dopamine 
D1-receptor related neural transmission (relevant for cognitive 
stability) (39). This pattern leads to an efficient balance between 
cognitive processes characterized by flexibility (e.g., readily 
allowing the processing of new sensory information driven by 
bottom-up influences) and stability (e.g., reducing distractibility 
and being driven by task goals in a top–down manner). Overall, 
cognitive flexibility and stability and the balance between them 
are crucial for executive functions (40).
PHArMAcOLOgicAL iNterveNtiONs—
cUrreNt PrActice AND cAveAts
Consequently, pharmacological interventions modulating these 
dopaminergic abnormalities are frequently used in the treat-
ment of several psychiatric symptoms or disorders. Selective 
dopamine D2 antagonists (neuroleptics) like Risperidone (41, 
42), for example, reduce the flexibility of mental representations 
upon administration. On the other hand, methylphenidate 
(MPH), a dopamine reuptake inhibitor commonly used to treat 
children with attention deficit/hyperactivity disorder, prolongs 
the availability of dopamine in the synaptic cleft and leads to 
stronger activation of dopamine D1 receptors. This leads to more 
stable mental representations, and thus provides a balance for 
the D2-mediated cognitive flexibility. MPH has previously been 
applied within the context of disorders like cancer (43–45), sickle 
cell disease (46), and neurofibromatosis type 1 (47).
While these approaches are characterized by good ecological 
validity, are readily accessible and carry low costs for families 
and health care providers, they are not without problems 
(see Figure  1). For one, studies have not consistently shown 
significant and beneficial effects in these cases. MPH-related 
increases of general IQ levels were reported in children with 
neurofibromatosis type 1 (47). Moreover, positive effects of low 
doses (0.3 mg/kg) of MPH on attention and social functioning 
in survivors of brain tumors and leukemia in childhood (44) 
were found, but do hardly generalize to academic performance 
tABLe 1 | Comparison of cognitive (executive function) training, pharmacological interventions and oscillation-based interventions on different dimensions currently 
defining individualized/personalized medicine [adapted from Ref. (5)].
Possible interventions for executive dysfunctions
Dimension Does the treatment… cognitive 
training
Pharmacological 
interventions
Oscillation-based 
interventions
Disease …consider the specific cognitive deficits? ++ + ++
Patient’s environment …consider environmental aspects of cognitive deficits? ++ – +
Genes …consider how genetic factors influence the cognitive deficits? – – –
Medication/Neurobiology …target the specific neurobiological basis of the cognitive deficits? – + ++
Other elements of health care …involve patient education and counseling specific for the cognitive deficits? ++ – ++
Information management …connect patient-specific and evidence-based information concerning the  
cognitive deficits?
– ++ ++
+ denotes that this treatment approach takes the respective dimension of individualized treatment into account.
++ denotes that this treatment approach takes the respective dimension of individualized treatment into account very well.
– denotes that this treatment approach does not take the respective dimension of individualized treatment into account.
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and success (45, 48). Similarly, children with sickle cell disease 
showed isolated MPH-related improvements in inhibitory con-
trol, while other executive functions and behavior resembling 
symptoms of attention-deficit hyperactivity disorder (ADHD) 
were not improved (46). Such mixed effects and the limited gen-
eralization may be explained by the fact that pharmacological 
interventions do not take the disease-specific cognitive profile 
and pathophysiological background into account, but function 
in a rather general fashion.
Thus, pharmacological interventions aiming to address cogni-
tive (executive function) deficits in survivors of severe illnesses 
are connected to a trial-and-error approach and to post  hoc 
hypotheses about why something has or has not been effective. 
This can lead to side effects concerning other cognitive functions 
and may interfere with pharmacological strategies addressing the 
somatic manifestations of the underlying disease. For example, 
pharmacological interventions targeting executive function 
deficits can induce cardio-metabolic changes and lowered arousal 
in the case of neuroleptics (49), and can lead to sleep problems, 
weight loss, and mood changes in the case of MPH (50). Therefore, 
medication may not always represent a practicable solution in 
clinical practice, also because it can, at least currently, hardly be 
tailored to the individual patients (see Table 1).
NeUrONAL OsciLLAtiONs AND tHeir 
reLevANce FOr eXecUtive 
FUNctiONs
As outlined above, both neuropsychological training approaches 
and pharmacological interventions are unable to address the 
individually different pattern of executive dysfunctions and the 
underlying pathophysiological background to a sufficient extent 
(see Table  1). In this regard, the use of treatment strategies 
targeting neuronal oscillations represents a possible and highly 
attractive option. The term “neuronal oscillations” refers to the 
synchronized and rhythmic electrical brain activity that can be 
measured on the head using EEG electrodes (51). Although there 
still are significant gaps in scientific knowledge concerning their 
functional relevance, some neuronal oscillations have already been 
linked to some specific cognitive functions [e.g., See Ref. (52)]. 
The theta frequency band (4–7 Hz), for example, seems to play 
one of the most important roles, as it has been shown to be closely 
linked to the level of cognitive control (53–55). Specifically, theta 
oscillations originating from medial frontal regions (e.g., the 
anterior cingulate cortex) have been associated with attentional 
and cognitive resource allocation (53). Johnson et al. (56) have 
demonstrated that theta oscillations are an essential element 
of bidirectional connections between prefrontal and parietal 
regions and are highly relevant for working memory processes. 
Thus, the suggested connection to executive functions is at least 
partially mediated via long-range network connectivity, for 
which synchronized theta oscillations play a central role (57, 58). 
Conversely, executive functions are functionally largely based on 
precisely such long-range networks (54, 59, 60). In addition to 
frontal-midline theta power, beta oscillations (15–20 Hz) are also 
a relevant element as they have been suggested to be reflective 
of the maintenance of the current cognitive state and thus likely 
also represent elements of alertness and attention (61). Further, 
alpha oscillations should also be considered, since they have 
been suggested to represent the controlled access to information 
stored in memory (56, 62) and thus are also relevant for execu-
tive functions. Importantly, in all cases, a variety of oscillation 
characteristics apart from the frequency per se, such as power/
amplitude, cross-frequency coupling, and phase locking, need to 
be considered in this context (51, 63, 64). Due to space limitations 
in the current paper, the interested reader is referred to a number 
of excellent reviews concerning neuronal oscillations in general 
and their relevance for executive functions in particular (53, 63, 
65–68). We propose that—if interpreted carefully and handled 
critically—this available and constantly expanding knowledge 
could be beneficial when attempting to ameliorate executive 
function deficits in children and (young) adults with severe acute 
or chronic conditions.
OsciLLAtiON-BAseD iNterveNtiONs 
FOr eXecUtive DYsFUNctiONs: 
NeUrOFeeDBAcK
Such attempts have already been successfully made in the treat-
ment of various pediatric (and adult) neuropsychiatric conditions 
in which neuronal oscillations have been shown to be altered [e.g., 
see Ref. (69, 70)]. One possibility of influencing these neuronal 
oscillations (and thus hopefully also the corresponding cognitive 
functions and behavior) is the application of frequency band 
neurofeedback training (71–73). Frequency band neurofeedback 
uses single EEG electrodes to record neuronal oscillations from 
the patient’s head. Via specifically designed software, these record-
ings are converted into animations or simple computer games 
(e.g., a car driving on a race course). The patient is able to control 
these games by regulating the relevant parameters of the EEG 
(i.e., the target oscillation). Neurofeedback is usually conducted 
over a period of 2–3 months with 1–2 weekly sessions. Originally, 
frequency band neurofeedback has been applied in the treatment 
of patients with ADHD, where a downregulation of theta activity 
and the complementary upregulation of beta activity is usually 
conducted (72, 74) and has shown encouraging effects on the 
level of symptoms (73, 75) and executive functions (71). Yet, it 
is likely that the efficacy of these protocols can be enhanced by 
training patients to upregulate theta power (76).
Importantly, depending on the individual profile of execu-
tive function problems, a similar approach may be applicable 
to patients, in whom the deficits stem from severe underlying 
somatic disorders or their treatment (see Figure 1). In fact, ben-
eficial effects of frequency-based neurofeedback on self-reported 
cognitive measures have already been demonstrated in a sample 
of breast cancer survivors who suffered from cognitive impair-
ments following treatment (77). Also, successful applications in 
patients with epilepsy (78) and chronic fatigue (79) have been 
reported. In contrast, one study has reported no significant dif-
ferences between neurofeedback and placebo feedback training 
in pediatric brain tumor survivors (80). In this context, however, 
only beta oscillations or sensorimotor rhythms (12–15 Hz) were 
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targeted, not taking theta frequencies, which play a crucial role in 
executive functioning, into account.
OsciLLAtiON-BAseD iNterveNtiONs 
FOr eXecUtive DYsFUNctiONs: 
trANscrANiAL stiMULAtiON 
tecHNiQUes
A less established approach may relate to the application of tran-
scranial alternating current stimulation (tACS). Through tACS, 
a weak electrical current (<2  mA) is repeatedly applied to the 
head of the patient at the desired current frequency (e.g., 6 Hz). 
The assumption is that, after repetitive “training,” the brain will 
adapt to and “take over” these externally delivered oscillations 
(81). tACS theta frequency stimulation over parietal regions 
has been shown to result in significantly increased working 
memory capacity in healthy adults (82). So far, a small number of 
tACS-intervention studies have been conducted in patients with 
neurological disorders like epilepsy (83) and Parkinson’s disease 
(84), but studies reporting long-term effects or the applicability 
in pediatric populations have not been published so far. Overall, 
tACS has been described as a safe, specific, and direct possibility 
to influence pathological changes in neuronal oscillations (81). 
Yet, to be efficient, the targeted executive function deficit needs to 
be directly relatable to the characteristics (amplitude, frequency, 
phase, or regional coherence) of a particular neuronal oscillation 
(i.e., the stimulation protocol needs to be hypothesis-driven) 
and the tACS-induced changes must be present after stimulation 
offset (81). For these reasons and since the functional relevance 
of the oscillations in question remains to be investigated further, 
tACS should be classified as a rather experimental, but promising 
approach at this stage. Interestingly, another neuromodulation 
approach (transcranial direct current stimulation (tDCS)) has 
recently been used in conjunction with a short behavioral train-
ing, with this specific combination of interventions leading to (i) 
significant working memory improvements and (ii) changes in 
theta/alpha oscillations in a small group of healthy controls (85). 
Although its effects on neuronal oscillations may be of a more 
indirect or supportive nature, tDCS could thus also constitute a 
promising and safe (86) approach in this regard.
cHALLeNges, ArisiNg POssiBiLities, 
AND FUtUre PersPectives FOr 
OsciLLAtiON-BAseD treAtMeNt 
APPrOAcHes
Approaches like frequency band neurofeedback or tACS/tDCS 
could thus potentially be used to up-/downregulate patient’s 
oscillatory activity in order to achieve changes in cognition 
and thus also in behavior. However, there are also a number of 
challenges associated with this approach. For example, it may be 
argued that norm values for the power of the different frequency 
bands are only very difficult to obtain (74). This is the case, since 
such values vary considerably inter- and intraindividually and 
also strongly depend on the conditions under which they are 
measured. Moreover, basing intervention protocols for patients 
on oscillatory power measured in healthy individuals could lead 
to the use of training protocols which may not be as efficient as 
presumed (76), since the neurophysiological characteristics of 
a patient are probably different due to the mere presence of a 
disease. These individual differences need to be addressed using 
individually adapted intervention approaches. Decisions about 
which frequency bands should be up-/downregulated have to be 
based on the individual profile of executive (dys)function and 
on the (expanding) knowledge about the oscillatory correlates of 
these functions (see Figure 1).
Overall, we envisage that a promising and effective clinical 
approach to executive function deficits occurring in survivors of 
severe acute or chronic illnesses involves the development and 
application of specific, individualized treatment possibilities. 
Precisely, this could take place using oscillation-based interven-
tion approaches. Currently, however, high initial costs (mainly for 
the equipment) and the resulting limited accessibility represent 
significant challenges for implementation. This is especially the 
case in more rural regions with a less developed medical infra-
structure. Yet, a very effective way of addressing both of these chal-
lenges at once are “e-health” and “home-treatment approaches,” 
which would be particularly feasible in the case of neurofeedback 
training. To achieve this, EEG amplifiers are being developed that 
are portable, robust, and cost-effective due to only a few inbuilt 
electrode channels necessary for neurofeedback. In the future, 
such home-treatment approaches could be used to apply the 
feedback using the patients’ own mobile devices or TV/computer 
screens in their home environment. Such neurofeedback systems 
could be used to either supplement treatment sessions taking 
place in clinical settings or within the framework of telehealth 
initiatives, in which the entire course of treatment takes place in 
the home environment of the patient. Either way, to adhere to 
best practice and ethical standards (87) and to avoid or address 
side effects should they occur (88), such approaches would need 
to involve the close support and monitoring by clinicians expe-
rienced in the field. This is necessary, since such novel treatment 
approaches are only suitable for motivated patients in whom 
the current psychosocial situation is stable and who do not have 
any immediately threatening health concerns. To establish such 
boundary conditions, it may in some cases be helpful to initially 
attempt to target major cognitive deficits in attention or impulse 
control using pharmacological strategies described above. Such a 
procedure has been used successfully in patients with ADHD (71).
Furthermore, elements from cognitive-behavioral therapy (and 
in fact also the aforementioned cognitive training approaches) 
are an essential part of neuronal oscillation-based treatment 
approaches (72, 85). In addition, for home-treatment approaches, 
families need to be provided with a detailed introduction to the 
technical aspects of the treatment (e.g., how to set up the system, 
connect electrodes, conduct troubleshooting). To account for all 
these factors, at least one initial direct contact between the clini-
cian and the patient family as well as regular follow-up contacts 
(potentially via phone or secure online platforms) are necessary. 
In addition, there also are ethical boundaries to consider in the 
case of home-treatment approaches that need to be monitored 
closely (e.g., financial constraints, involvement of health care 
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provider and insurances, treatment offered by non-healthcare 
proficient sources). Finally, it remains to be clarified how any 
treatment outcomes could be effectively measured and quantified. 
This could potentially be achieved through the use of standard-
ized cognitive test batteries which carry a high ecological validity.
So far, only one study has reported some outcomes of a partial 
neurofeedback home-treatment (89). Unfortunately, no control 
treatment was used and reported statistical analyses are limited 
to descriptions of individual symptom trajectories. This study, 
however, incorporates a detailed methodological description, 
and discusses a number of important considerations as well as 
possible pitfalls. More recently, alpha-frequency neurofeedback 
using a portable device has been shown to improve memory in a 
group of healthy adults (90). In addition, some home-treatment 
approaches have been reported concerning other biological 
parameters like electromyographic measures (91) and gait (92). 
Although these studies only report preliminary results, they 
nevertheless encourage further developments of these technolo-
gies. Through such developments, oscillations-based treatment 
options would not only become less costly, more widely available, 
and easy-to-use, but would also significantly enhance transfer-
ability of training success to daily life.
sUMMArY
In sum, we postulate that survivors of severe pediatric illnesses 
could greatly benefit from oscillation-based intervention 
approaches as they have the potential to ameliorate executive 
dysfunctions, thus leading to significant improvements in daily 
life. To benefit from the effects of neuronal plasticity, such 
approaches should be considered as early on in development 
as possible. Based on their high functional relevance for execu-
tive functions and the experience gained from interventions in 
areas like ADHD, targeting theta oscillations via neurofeedback 
could be a good starting point. Such approaches would provide 
new opportunities for the treating clinicians as they would 
close existing gaps between (pediatric) psychology, (neuro)
pediatrics, and basic research, consequently leading to better 
clinical care for the affected children, (young) adults, and their 
families.
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